Ulobetasolum

Ulobetasolum Uses, Dosage, Side Effects, Food Interaction and all others data.

Ulobetasolum is a highly potent corticosteroid. It is structurally related to clobetasol. Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses.

Ulobetasolum was granted FDA approval on 17 December 1990.

Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals. Ulobetasolum has a moderate duration of action as it is applied once or twice daily. Corticosteroids have a wide therapeutic window as patients may require doses that are multiples of what the body naturally produces. Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.

Ulobetasolum
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Ulobetasolum
Generic	Ulobetasol
Ulobetasol Other Names	21-chloro diflorasone, Halobetasol, Ulobetasol, Ulobétasol, Ulobetasolum
Type
Formula	C₂₂H₂₇ClF₂O₄
Weight	Average: 428.9 Monoisotopic: 428.1565934
Protein binding	Ulobetasol is likely bound to corticosteroid binding globulin in serum.
Groups	Approved
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Ulobetasolum is a lipocortin corticosteroid used to treat inflammatory and pruritic corticosteroid-responsive dermatoses.

Ulobetasolum cream and ointment are indicated in the treatment of inflammatory and pruritic corticosteroid responsive dermatoses. Ulobetasolum lotion is indicated in the treatment of plaque psoriasis.

Ulobetasolum is also used to associated treatment for these conditions: Psoriasis Vulgaris (Plaque Psoriasis), Corticosteroid responsive, Inflammatory Dermatosis, Corticosteroid responsive, pruritic Dermatosis

How Ulobetasolum works

The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation. Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days.

Glucocorticoids inhibit phospholipase 2 and neutrophil apoptosis and demargination, resulting in decreased formation of arachidonic acid derivatives. They also inhibit NF-Kappa B and other inflammatory transcription factors while promoting anti-inflammatory genes like interleukin-10.

Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive. High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels.

Toxicity

Data regarding acute overdoses of glucocorticoids are rare. Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency. Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.

Food Interaction

No interactions found.

Elimination Route

Ulobetasolum lotion reaches a C_max of 201.1 ± 157.5 pg/mL, with a T_max of 3 hours, and an AUC of 1632 ± 1147 pg*h/mL. Absorption can be influenced by skin integrity, the vehicle used, inflammation, or disease processes.